Skip to main content

Table 2 Baseline features and symptom outcome in ROM patients suffering from MDD

From: The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice

 

All MDD patients (n=598)

Patients who received psychotherapy only (n=80)

Age (in years)

39.3 (SD 11.3)

36.2 (SD 10.8)

Gender (% female)

66.7% (n= 399)

73.8% (n=59)

MADRS pre treatment

25.9 (SD 6.5)

24.1 (SD 6.0)

MADRS post treatment

18.2 (SD 9.4)

16.5 (SD 9.1)

Treatment outcome

  

Within-Group Effectsize1

1.16

1.28

Proportion of responders2

29.1%

35.0%

Proportion of remitters3

22.6%

27.5%

Ethnicity

  

Netherlands

84.8%

76.4%

Turkey/Morocco

5.1%

5.5%

Suriname/Antilles

3.1%

4.2%

Other

7.0%

13.9%

Marital Status

  

Married/Cohabitating

52.8%

44.4%

Divorced/Widowed

16.6%

22.2%

Single/LAT

30.0%

33.3%

Employment Status

  

Employed

34.3%

34.7%

Not Employed

26.1%

34.7%

Sickness Benefit

39.0%

30.6%

Retired

0.6%

0%

Educational level

  

Low

12.3%

9.7%

Intermediate low

33.1%

23.6%

Intermediate high

38.4%

40.3%

High

16.2%

26.4%

  1. Caption:
  2. 1 Within Group Effectsize is a definition of treatment outcome often used in PETs and defined as: the extent of improvement (Δ MADRS pre- and post treatment within the group under investigation) adjusted for the standard deviation pre treatment.
  3. 2 Response is defined as a 50% reduction of symptoms on the MADRS.
  4. 3 Remission is defined as MADRS≤10.